Education
About Us
Working with TipRanks
Follow Us
Sonova Holding AG Unsponsored ADR (SONVY)
OTHER OTC:SONVY
Top Page
Sonova Holding AG
(OTC:SONVY)
Rating:67Neutral
Price Target:
$67.00
▲(16.12%Upside)
Sonova Holding AG (SONVY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.73B
Dividend Yield1.08%
Average Volume (3M)14.63K
Price to Earnings (P/E)28.5
Beta (1Y)0.81
Revenue Growth6.46%
EPS Growth-10.22%
CountryUS
Employees18,335
SectorHealthcare
Sector Strength40
IndustryMedical - Devices
Share Statistics
EPS (TTM)1.71
Shares Outstanding298,134,030
10 Day Avg. Volume512
30 Day Avg. Volume14,629
Financial Highlights & Ratios
PEG Ratio-3.94
Price to Book (P/B)5.13
Price to Sales (P/S)0.00
P/FCF Ratio22.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$67.00Price Target Upside16.12% Upside
Rating ConsensusHold
Number of Analyst Covering0
Sonova Holding AG Business Overview & Revenue Model
Company DescriptionSonova Holding AG designs, develops, manufactures, and distributes hearing care solutions for adults and children. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The company offers wireless communication products; rechargeable hearing aids; wireless headsets, speech enhanced hearables, audiophile headphones, microphones, and wireless transmission systems; and audiological care services. It also provides hearing instruments under the Phonak, Unitron, and Hansaton brand names; cochlear implants under the Advanced Bionics brand; consumer hearing products under the Sennheiser brand; and audiological care services under the AudioNova, Audium, Audition Santé, Boots Hearingcare, Connect Hearing, Geers, Hansaton, Lapperre, Schoonenberg, and Triton brands. The company sells its products through independent distributors; and provides hearing care services through a network of approximately 3,600 stores and clinics. It operates in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.
How the Company Makes MoneySonova Holding AG generates revenue through the sale of its hearing care products and services. The company’s primary revenue streams include the sale of hearing instruments, which contribute significantly to its earnings. Additionally, Sonova makes money from cochlear implants and related services, which provide another crucial revenue source. The company also benefits from its network of audiological care services and retail audiology stores, which enhance customer access to its products. Key partnerships with healthcare professionals, clinics, and distributors worldwide further support its sales efforts. Sonova's ongoing investment in research and development enables it to maintain a competitive edge, driving innovation and new product introductions that bolster its revenue growth.
Sonova Holding AG Earnings Call Summary
Earnings Call Date:May 09, 2025
(Q2-2025)
| % Change Since: -4.91%|
Next Earnings Date:Nov 14, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed view with strong product launch feedback and solid sales growth, particularly in cochlear implants, but faced profitability pressures and challenging market conditions, especially in the Audiological Care segment.Q2-2025 Updates
Positive Updates
Solid Sales Growth
Sonova Holding AG reported a solid sales growth of 5.9% in local currencies for the first half of fiscal year 2024-2025, driven by hearing instruments and cochlear implants.
Cochlear Implant Segment Performance
The cochlear implant business showed strong momentum with a 12.5% growth for the first half of the fiscal year, with system sales up by 18.2%.
Positive Product Launch Feedback
The launch of Infinio and Sphere received very positive feedback, with a high share of Sphere Infinio supporting strong ASP uplift.
Negative Updates
Profitability Pressures
Sonova reported a decrease in adjusted EBITA by 3.7% in local currency, due to launch costs, lower ASPs, and high lead generation costs in the Audiological Care business.
Challenging Market Conditions
The company faced challenging market conditions, particularly in the consumer hearing business and in Europe, where growth was muted.
Audiological Care Growth
Audiological Care reported an organic growth of only 1.1%, impacted by market conditions and consumer confidence, with elevated lead generation costs.
Company Guidance
During the Sonova Holding AG Half Year Results 2024-2025 Conference Call, the company provided guidance confirming expectations for both top-line and bottom-line growth for the fiscal year. They reported a solid sales growth of 5.9% in local currencies, primarily driven by a 7% increase in the Hearing Instruments segment and a 12.5% growth in Cochlear Implants. The new Sphere and Infinio products, launched in August and September, received positive feedback, contributing to a strong momentum anticipated to carry into the second half of the year. The company acknowledged challenges such as market conditions, lead generation costs, and headwinds from the Swiss franc. However, they expressed confidence in achieving their guidance, supported by structural cost improvements, and strategic initiatives expected to enhance operating efficiency and profitability. Sonova highlighted a projected uplift in ASP (Average Selling Price) contributing positively to EBITDA growth, alongside incremental volume increases.Sonova Holding AG Financial Statement Overview
Summary
Sonova Holding AG demonstrates strong financial performance with consistent revenue growth, effective cost management, and robust cash flow generation. The company maintains a stable capital structure with low leverage, although slight increases in liabilities should be monitored.Income Statement
Sonova Holding AG demonstrates strong profitability with a consistent gross profit margin of approximately 72% and a solid net profit margin of 14% for the latest fiscal year. The company has shown a stable revenue growth rate of 7% from the previous year, indicating healthy business expansion. The EBIT margin stands at 18%, and the EBITDA margin is at 24%, both reflecting effective cost management and operational efficiency.82
Very Positive
Balance Sheet
The balance sheet of Sonova Holding AG shows a robust equity ratio of 45%, highlighting a stable capital structure. The debt-to-equity ratio is relatively low at 0.66, indicating manageable leverage levels. Return on equity is strong at 20%, showcasing effective utilization of shareholder funds. However, the total liabilities have slightly increased, which requires monitoring.78
Positive
Cash Flow
Cash flow analysis reveals a healthy operating cash flow to net income ratio of 1.47, suggesting strong cash generation relative to net earnings. The free cash flow has grown by 5% compared to the previous year, and the free cash flow to net income ratio is 1.21, indicating efficient cash management and sufficient free cash flow for reinvestment or debt reduction.85
Very Positive
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.87B | 3.63B | 3.74B | 3.36B | 2.60B |
| Gross Profit | 2.78B | 2.62B | 2.59B | 2.42B | 1.84B |
| EBITDA | 927.00M | 921.70M | 978.70M | 960.90M | 755.30M |
| Net Income | 540.50M | 601.00M | 647.50M | 649.00M | 581.00M |
Balance Sheet | |||||
| Total Assets | 5.92B | 5.79B | 5.55B | 5.59B | 5.93B |
| Cash, Cash Equivalents and Short-Term Investments | 687.10M | 513.80M | 414.80M | 612.00M | 1.77B |
| Total Debt | 1.76B | 1.79B | 1.81B | 1.48B | 1.83B |
| Total Liabilities | 3.24B | 3.30B | 3.32B | 3.16B | 3.15B |
| Stockholders Equity | 2.66B | 2.47B | 2.21B | 2.41B | 2.75B |
Cash Flow | |||||
| Free Cash Flow | 656.10M | 624.70M | 609.10M | 815.90M | 665.50M |
| Operating Cash Flow | 793.70M | 753.30M | 763.40M | 922.50M | 754.70M |
| Investing Cash Flow | -212.70M | -234.00M | -429.50M | -707.00M | -123.60M |
| Financing Cash Flow | -401.80M | -415.30M | -523.50M | -1.37B | 687.60M |
Sonova Holding AG Technical Analysis
Negative
57.70
Price Trends
61.43
Negative
60.57
Negative
64.74
Negative
Market Momentum
-0.94
Positive
34.59
Neutral
1.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SONVY, the sentiment is Negative. The current price of 57.7 is below the 20-day moving average (MA) of 59.30, below the 50-day MA of 61.43, and below the 200-day MA of 64.74, indicating a bearish trend. The MACD of -0.94 indicates Positive momentum. The RSI at 34.59 is Neutral, neither overbought nor oversold. The STOCH value of 1.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SONVY.
Sonova Holding AG Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $13.12B | 31.81 | 7.86% | 3.08% | 5.16% | 56.79% | |
75 Outperform | $16.32B | 35.67 | 17.42% | 0.37% | -1.14% | -16.35% | |
73 Outperform | $20.36B | 52.55 | 37.92% | ― | 23.49% | 71.25% | |
69 Neutral | $14.69B | 35.02 | 5.15% | ― | 6.88% | 21.11% | |
67 Neutral | $16.73B | 28.48 | 21.18% | 1.08% | 6.46% | -10.22% | |
59 Neutral | $14.64B | 136.07 | -8.96% | 2.38% | -20.17% | -138.32% | |
52 Neutral | $7.53B | 0.20 | -63.81% | 2.31% | 16.15% | 0.40% |
* Healthcare Sector Average
Performance Comparison
SONVY
Sonova Holding AG
57.30
-2.62
-4.37%
BAX
Baxter International
28.25
-6.48
-18.66%
COO
Cooper Co
72.20
-17.94
-19.90%
PODD
Insulet
289.99
88.60
43.99%
SNN
Smith & Nephew Snats
29.33
2.28
8.43%
WST
West Pharmaceutical Services
221.05
-107.10
-32.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.